Exhibit 99.2
Contact: | Adam C. Derbyshire | G. Michael Freeman | ||
Executive Vice President | Associate Vice President, Investor Relations | |||
and Chief Financial Officer | and Corporate Communications | |||
919-862-1000 | 919-862-1000 |
SALIX PHARMACEUTICALS TO PRESENT AT
TWO INVESTMENT CONFERENCES IN MAY
RALEIGH, NC, May 6, 2014 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at two investment conferences during May 2014. Information regarding these conferences is provided below:
Bank of America Merrill Lynch 2014 Health Care Conference | ||||
Las Vegas, NV | Tuesday, May 13 | 10:40 a.m. / 1:40 p.m. (ET) | ||
UBS Global Healthcare Conference | ||||
New York, NY | Monday, May 19 | 10:00 a.m. |
Interested parties can access a live audio web cast of the presentation athttp://www.salix.com. A replay of the presentation will be available at the same location.
About Salix
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products and medical devices for the prevention and treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic products, complete any required development and regulatory submission of these products, and commercialize them through the Company’s 500-member specialty sales force.
1
Salix trades on the NASDAQ Global Select Market under the ticker symbol “SLXP”.
For more information, please visit our Website atwww.salix.com or contact Salix at 919-862-1000. Follow us on Twitter (@SalixPharma) and Facebook (www.facebook.com/SalixPharma). Information on our Twitter feed, Facebook page and web site is not incorporated in our filings with the SEC.
2